X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs DIVIS LABORATORIES - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD DIVIS LABORATORIES STRIDES SHASUN LTD/
DIVIS LABORATORIES
 
P/E (TTM) x 15.3 31.3 49.0% View Chart
P/BV x 1.8 5.4 32.8% View Chart
Dividend Yield % 0.6 0.9 60.9%  

Financials

 STRIDES SHASUN LTD   DIVIS LABORATORIES
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-17
DIVIS LABORATORIES
Mar-17
STRIDES SHASUN LTD/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,2751,222 104.3%   
Low Rs918784 117.1%   
Sales per share (Unadj.) Rs389.6153.1 254.4%  
Earnings per share (Unadj.) Rs28.039.9 70.0%  
Cash flow per share (Unadj.) Rs48.944.6 109.7%  
Dividends per share (Unadj.) Rs4.5010.00 45.0%  
Dividend yield (eoy) %0.41.0 41.2%  
Book value per share (Unadj.) Rs303.1201.8 150.2%  
Shares outstanding (eoy) m89.42265.47 33.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.86.6 43.0%   
Avg P/E ratio x39.225.1 156.1%  
P/CF ratio (eoy) x22.422.5 99.7%  
Price / Book Value ratio x3.65.0 72.8%  
Dividend payout %16.125.0 64.3%   
Avg Mkt Cap Rs m98,036266,266 36.8%   
No. of employees `0005.89.7 59.6%   
Total wages/salary Rs m5,8814,687 125.5%   
Avg. sales/employee Rs Th6,005.94,175.0 143.9%   
Avg. wages/employee Rs Th1,014.0481.5 210.6%   
Avg. net profit/employee Rs Th431.21,089.3 39.6%   
INCOME DATA
Net Sales Rs m34,83440,643 85.7%  
Other income Rs m1,686749 225.1%   
Total revenues Rs m36,52041,392 88.2%   
Gross profit Rs m6,42814,460 44.5%  
Depreciation Rs m1,8721,233 151.7%   
Interest Rs m2,26923 10,041.2%   
Profit before tax Rs m3,97313,953 28.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m40-   
Extraordinary Inc (Exp) Rs m-1,0060-   
Tax Rs m4703,349 14.0%   
Profit after tax Rs m2,50110,604 23.6%  
Gross profit margin %18.535.6 51.9%  
Effective tax rate %11.824.0 49.3%   
Net profit margin %7.226.1 27.5%  
BALANCE SHEET DATA
Current assets Rs m38,16540,105 95.2%   
Current liabilities Rs m30,4026,595 461.0%   
Net working cap to sales %22.382.5 27.0%  
Current ratio x1.36.1 20.6%  
Inventory Days Days77119 65.2%  
Debtors Days Days10481 129.5%  
Net fixed assets Rs m37,63919,995 188.2%   
Share capital Rs m894531 168.4%   
"Free" reserves Rs m26,21053,043 49.4%   
Net worth Rs m27,10553,574 50.6%   
Long term debt Rs m16,3770-   
Total assets Rs m81,16861,585 131.8%  
Interest coverage x2.8618.4 0.4%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.7 65.0%   
Return on assets %5.917.3 34.1%  
Return on equity %9.219.8 46.6%  
Return on capital %12.126.1 46.2%  
Exports to sales %00-   
Imports to sales %025.2 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA10,259 0.0%   
Fx inflow Rs m13,46535,384 38.1%   
Fx outflow Rs m4,07610,399 39.2%   
Net fx Rs m9,38924,985 37.6%   
CASH FLOW
From Operations Rs m2,88111,493 25.1%  
From Investments Rs m-7,051-11,372 62.0%  
From Financial Activity Rs m3,382-93 -3,632.9%  
Net Cashflow Rs m-78828 -2,773.1%  

Share Holding

Indian Promoters % 27.7 52.0 53.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 11.8 320.3%  
FIIs % 8.6 19.0 45.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 17.2 150.6%  
Shareholders   56,241 31,796 176.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   STERLING BIOTECH  PFIZER  ALKEM LABORATORIES  ORCHID PHARMA LTD  SANOFI INDIA  

Compare STRIDES SHASUN LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Crash in Bitcoin, Correction in MidCap and SmallCap Indices and Top Stocks in Action Today(Pre-Open)

The past year has seen the BSE MidCap and BSE SmallCap indices surging by 43.1% and 57.1% respectively. Taking a two year view these indices have produced mind-boggling return of 75.3% .

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Jan 16, 2018 (Close)

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD - ALEMBIC LTD COMPARISON

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS